Top in hem/onc: Antihypertensive drugs in colorectal cancer, CAR-T for brain tumors
In a recent study, researchers found that antihypertensive drugs could potentially reduce mortality among patients with stage I to stage III colorectal cancer. It was the top story in hematology/oncology last week.
In other news, researchers said they were “extraordinarily optimistic” about the possibility of using chimeric antigen receptor (CAR) T-cell therapy for pediatric brain cancer. Currently, treatment options are limited for patients with aggressive disease and those who are not candidates for surgery due to tumor location.
Read these and more top stories in hematology/oncology below:
Antihypertensive drugs ‘potentially prolong life’ for patients with colorectal cancer
Low-cost antihypertensive drugs appeared to be associated with reductions in colorectal cancer-specific mortality among patients with stage I to stage III disease, according to results of a retrospective analysis published in Cancer Medicine. Read more.
Researchers ‘extraordinarily optimistic’ about potential of CAR-T for pediatric brain cancer
Brain and central nervous system tumors are the second most common malignancy among children and the most prevalent form of solid tumor, according to American Cancer Society data. Read more.
Enhertu receives breakthrough therapy designation for second-line breast cancer treatment
The FDA granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) for second-line treatment of patients with metastatic HER2-positive breast cancer. Read more.
Mount Sinai Comprehensive BRCA Program takes ‘patient-centric’ approach
Genomic testing has afforded today’s patient the advantage of knowing when they harbor a potentially dangerous genetic mutation, such as BRCA1 or BRCA2. Read more.
‘Science of trustworthiness’ key to reducing cancer disparities
Reducing disparities in cancer care requires an understanding of “the science of trustworthiness” and a greater focus on social determinants of health, according to a leader in health equity research. Read more.